Cubist Pharmaceuticals Inc (CBST)

101.94
0.14 0.14
NASDAQ : Health Care
Prev Close 101.80
Open 101.98
Day Low/High 101.94 / 101.99
52 Wk Low/High 58.50 / 101.99
Volume 8.02M
Avg Volume 2.65M
Exchange NASDAQ
Shares Outstanding 76.30M
Market Cap 7.78B
EPS -0.27
P/E Ratio 124.15
Div & Yield N.A. (N.A)

Latest News

Cubist Announces Withdrawal Of Listing Of CVRs (CBSTZ) From NASDAQ Global Select Market

Cubist Announces Withdrawal Of Listing Of CVRs (CBSTZ) From NASDAQ Global Select Market

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will voluntarily withdraw the contingent value rights (CVRs) it issued under a Contingent Value Rights Agreement dated October 24, 2013 (CVR Agreement)...

Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers

Orphan Drug Company NPS Pharmaceuticals May Find Few Buyers

Shire has cash for what could be a $5 billion deal, but treatment base is limited.

Jim Cramer on the Markets: Some Stocks You Just Can't Ignore

Jim Cramer on the Markets: Some Stocks You Just Can't Ignore

And stop chasing stocks that won't let you in.

Cubist Pharmaceuticals (CBST): Today's Pre-Market Leader Stock

Cubist Pharmaceuticals (CBST): Today's Pre-Market Leader Stock

Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a pre-market leader candidate

Cubist Pharmaceuticals (CBST) Showing Signs Of Being A Momo Momentum Stock

Cubist Pharmaceuticals (CBST) Showing Signs Of Being A Momo Momentum Stock

Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a momo momentum candidate

Merck Begins Tender Offer To Acquire Cubist

Merck Begins Tender Offer To Acquire Cubist

Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc.

CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Cubist Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Merck & Co. Inc. - CBST

CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces The Investigation Of Cubist Pharmaceuticals, Inc. Over The Proposed Sale Of The Company To Merck & Co. Inc. - CBST

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Cubist Pharmaceuticals

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Cubist...

CBST SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Launches Investigation Of The Board Of Directors Of Cubist Pharmaceuticals, Inc. In Connection With The Fairness Of The Sale Of The Company To Merck & Co.

CBST SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Launches Investigation Of The Board Of Directors Of Cubist Pharmaceuticals, Inc. In Connection With The Fairness Of The Sale Of The Company To Merck & Co.

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Cubist Pharmaceuticals, Inc.

Health Care Stocks: A Year in Review and Predictions for 2015

Health Care Stocks: A Year in Review and Predictions for 2015

In 2014 drugmakers long on cash but short on growth bought quick access to markets that would have otherwise taken years to build. Can this continue?

Merck May Have Paid $2B-$3B Too Much For Cubist, Analyst Says

Merck May Have Paid $2B-$3B Too Much For Cubist, Analyst Says

Shares of Merck are tumbling after a Delaware court denied Cubist's bid to stop Hospira from selling a generic version of Cubicin in 2016.

Cubist Pharmaceutical (CBST) Stock Declines Today Following Patent Rejection

Cubist Pharmaceutical (CBST) Stock Declines Today Following Patent Rejection

Cubist Pharmaceutical (CBST) shares declined after a judge revoked all but one of the patents on the company's highest selling drug treatment.

Jim Cramer on the Stock Market: Thoughts on Merck's Deal for Cubist

Jim Cramer on the Stock Market: Thoughts on Merck's Deal for Cubist

Investing in safer hospital stays.

Cubist Pharmaceuticals (CBST) Is Today's Perilous Reversal Stock

Cubist Pharmaceuticals (CBST) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a "perilous reversal" (up big yesterday but down big today) candidate

Jim Cramer's Top Stock Picks: DIS SBUX NKE ENB MRK CRZO

Jim Cramer's Top Stock Picks: DIS SBUX NKE ENB MRK CRZO

The recent selloff means it's time to buy Disney, Starbucks, Nike and Enbridge, Cramer says.

Jim Cramer's 'Mad Money' Recap: Why You Should Buy Disney, Starbucks, Nike Now

Jim Cramer's 'Mad Money' Recap: Why You Should Buy Disney, Starbucks, Nike Now

Not only do all three have impressive growth, but they benefit from falling oil prices, Cramer says.

Cubist Comments On CUBICIN Patent Litigation

Cubist Comments On CUBICIN Patent Litigation

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the U.

Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low

Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low

Oil prices were a sinking ship on Monday, capsizing energy stocks and almost everything else caught in their wake.

Stocks Recover From Session Lows Though Oil Prices Continue to Hurt

Stocks Recover From Session Lows Though Oil Prices Continue to Hurt

Plunging crude oil prices and a selloff in energy stocks are weighing on benchmark indices again on Monday, limiting potential gains spurred by a rally among pharmaceuticals.